---
title: "Acura Pharmaceuticals Receives $300,000 From AD Pharma; Secured Note Balance Reaches $9.89 Million at 5.25%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278620552.md"
description: "Acura Pharmaceuticals has amended its secured promissory note with Abuse Deterrent Pharma, receiving $300,000 in new advances. The total principal now stands at $9.89 million, with accrued interest of approximately $1.04 million at a rate of 5.25%. The note matures on June 30, 2026, and the funds will be used to support daily operations while seeking additional financing."
datetime: "2026-03-10T21:53:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278620552.md)
  - [en](https://longbridge.com/en/news/278620552.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278620552.md)
---

# Acura Pharmaceuticals Receives $300,000 From AD Pharma; Secured Note Balance Reaches $9.89 Million at 5.25%

Acura Pharmaceuticals amended its secured promissory note with Abuse Deterrent Pharma to record new advances totaling $300,000 funded on Feb 6, Feb 13, and Mar 9, 2026. Including prior loans and $2.32 million under the Nov 10, 2022 note, principal stands at $9.89 million with about $1.04 million of accrued interest as of Feb 28, 2026, bearing interest at 5.25% (7.5% on overdue amounts). The note currently matures on Jun 30, 2026. Proceeds will support day-to-day operations while the company seeks additional financing.

**Agreement details:**

-   **Agreement type**: Secured promissory note; amended loan schedule with additional advances
-   **Counterparty**: Abuse Deterrent Pharma
-   **Signed / Effective**: Mar 09 2026 / same
-   **Duration / Termination**: Through Jun 30 2026
-   **Reason**: Support day-to-day operations and liquidity

Original SEC Filing: ACURA PHARMACEUTICALS, INC \[ ACUR \] - 8-K - Mar. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [ACXP.US](https://longbridge.com/en/quote/ACXP.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md)
- [Aspire Biopharma Completes $21 Million Private Placement Financing](https://longbridge.com/en/news/283061868.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [Lbp Am Sa Acquires 22,918 Shares of Vertex Pharmaceuticals Incorporated $VRTX](https://longbridge.com/en/news/282981307.md)
- [Goldman Sachs Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)](https://longbridge.com/en/news/283014601.md)